Menu

Japanese drugmaker Takeda announced its cancer medication Ninlaro will be subject to its 340B contract pharmacy policy.

Takeda to Expand 340B Contract Pharmacy Restrictions

January 17, 2024 Rich Daly, Editor in Chief 340B Report Views

Just days prior to implementing its first contract pharmacy restrictions, Japanese pharmaceutical giant Takeda yesterday announced it will increase the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Rich Daly

HRSA Announces 340B Webinar for Grantees Before Upcoming Recertification Begins

Unlocking the Value of 340B Consultants: Their Roles and Responsibilities